Yahoo
NYSE - Nasdaq Real Time Price USD

Alcon Inc. (ALC)

73.63 +2.18 (+3.05%)
At close: November 2 at 4:00:02 PM EST
73.63 0.00 (0.00%)
After hours: November 2 at 4:23:46 PM EST
Trade Alcon on Coinbase
Chart Range Bar
Loading chart for ALC
Chart does not reflect overnight price.
  • Previous Close 71.45
  • Open 72.06
  • Bid --
  • Ask --
  • Day's Range 72.04 - 74.19
  • 52 Week Range 61.83 - 87.64
  • Volume 2,199,194
  • Avg. Volume 1,677,576
  • Market Cap (intraday) 35.593B
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) 55.78
  • EPS (TTM) 1.32
  • Earnings Date Nov 10, 2026
  • Forward Dividend & Yield 0.36 (0.49%)
  • 1y Target Est 81.98
  • Morningstar Rating Rating available with Stock Picks access

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. In addition it also develops and commercializes therapies for chronic eye diseases, focusing on encapsulated cell therapy platforms for ocular conditions. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

www.alcon.com

25,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

ALC
6.71%
MSCI WORLD (^990100-USD-STRD)
8.67%

1-Year Return

ALC
0.14%
MSCI WORLD (^990100-USD-STRD)
10.35%

3-Year Return

ALC
3.00%
MSCI WORLD (^990100-USD-STRD)
73.18%

5-Year Return

ALC
11.20%
MSCI WORLD (^990100-USD-STRD)
51.85%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 2.82B
Earnings --
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
500M
1B
2B
2B
3B
0.0%
2.0%
4.0%
6.0%
8.0%

Analyst Insights

View More

Analyst Price Targets

62.00 Low
81.98 Average
73.63 Current
103.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 11/2/2026
Analyst Needham
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 98 -> 98

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.92%

  • Return on Assets (ttm)

    2.80%

  • Return on Equity (ttm)

    2.94%

  • Revenue (ttm)

    10.86B

  • Net Income Avi to Common (ttm)

    643M

  • Diluted EPS (ttm)

    1.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.46B

  • Total Debt/Equity (mrq)

    24.54%

  • Levered Free Cash Flow (ttm)

    1.27B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: